Insilico Medicine's AI Drug Posts 40% Response Rate in Treatment-Resistant Mesothelioma
· techtimes.com · popularity 18/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
AI drug discovery mesothelioma: Insilico Medicine's generative AI platform Chemistry42 produced ISM6331, an oral pan-TEAD inhibitor that posted a 40% objective response rate in heavily pretreated mesothelioma patients at ESMO 2026, advancing the clinical case for generative chemistry as a new approach to oncology drug design.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 12.